Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)

NCT00686543 | Completed Phase 4 Results

• 2 other identifiers: P05115EudraCT No. 2007-003148-31
• Study Type: interventional
• Target: 75
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this study is: to explore the potential for different dosing strategies of posaconazole oral suspension (POS) to increase plasma levels and to profile the pharmacokinetics of these dosing strategies in patients with compromised gastrointestinal function and at high risk for Invasive Fungal Infection.

Conditions

Fungal Infection; Acute Myelogenous Leukemia; Neutropenia

Keywords

Antifungal Agents; Anti-Infective Agents

Outcome Measures

Primary Outcomes (6)

• Mean POS Plasma Concentrations on Days 2, 3, and 8.

  Individual mean concentrations were calculated as the average of observed concentrations at 0 hour (before the morning dose) and 5 hours after the morning dose.

  Predose (0 hour) and 5 hours postdose on Days 2, 3, and 8

• Mean POS Plasma Concentrations on Days 8 and 15 Stratified by Randomized Dosing Regimen

  Individual mean concentrations were calculated as the average of observed concentrations at 0 hour (before the morning dose) and 5 hours after the morning dose.

  Predose (0 hour) and 5 hours postdose on Days 8 and 15

• Participants With a Mean POS Plasma Concentration ≥/<250 ng/mL on Day 3 and ≥/<500 ng/mL on Day 8

  Individual mean concentrations were calculated as the average of observed concentrations at 0 hour (before the morning dose) and 5 hours after the morning dose.

  Predose (0 hour) and 5 hours postdose on Days 3 and 8

• Participants With a Mean POS Plasma Concentration ≥/<350 ng/mL on Day 3 and ≥/<700 ng/mL on Day 8

  Individual mean concentrations were calculated as the average of observed concentrations at 0 hour (before the morning dose) and 5 hours after the morning dose.

  Predose (0 hour) and 5 hours postdose on Days 3 and 8

• Participants With a Mean POS Plasma Concentration ≥/<250 ng/mL on Day 8 and ≥/<500 ng/mL on Day 15

  Individual mean concentrations calculated as the average of observed concentrations at 0 hour (before the morning dose) and 5 hours after the morning dose.

  Predose (0 hour) and 5 hours postdose on Days 8 and 15

• Participants With a Mean POS Plasma Concentration ≥/<350 ng/mL on Day 8 and ≥/<700 ng/mL on Day 15

  Individual mean concentrations were calculated as the average of observed concentrations at 0 hour (before the morning dose) and 5 hours after the morning dose.

  Predose (0 hour) and 5 hours postdose on Days 8 and 15

Study Arms (3)

POS 200 mg TID Days 1-8 Followed by POS 200 mg TID Days 9-15

EXPERIMENTAL

POS 200 mg three times a day (TID) on Days 1-8 followed by continued randomized dosing regimen of POS 200 mg TID on Days 9-15, administered with food or oral nutritional supplements.

Drug: Posaconazole

POS 200 mg TID Days 1-8 Followed by POS 400 mg BID Days 9-15

EXPERIMENTAL

POS 200 mg TID on Days 1-8 followed by randomized dosing regimen of POS 400 mg twice a day (BID) on Days 9-15, administered with food or oral nutritional supplements.

Drug: Posaconazole

POS 200 mg TID Days 1-8 Followed by POS 400 mg TID Days 9-15

EXPERIMENTAL

POS 200 mg TID on Days 1-8 followed by randomized dosing regimen of POS 400 mg TID on Days 9-15, administered with food or oral nutritional supplements.

Drug: Posaconazole

Interventions

Posaconazole DRUG

Posaconazole will be used for prophylaxis

Also known as: SCH 056592 - NOXAFIL®

POS 200 mg TID Days 1-8 Followed by POS 200 mg TID Days 9-15; POS 200 mg TID Days 1-8 Followed by POS 400 mg BID Days 9-15; POS 200 mg TID Days 1-8 Followed by POS 400 mg TID Days 9-15

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects \>=18 years of age
• High risk of poor enteral medication absorption, based on the effects of cytotoxic chemotherapy, as evidenced by, but not limited to, mucositis, nausea, vomiting, and diarrhea, at baseline.
• High risk of invasive fungal infection (IFI) based on anticipated or documented prolonged neutropenia (absolute neutrophil count \[ANC\] \<500/mm\^3 \[0.5 x 10\^9/L\]).
• Clinical laboratory safety tests within normal limits or clinically acceptable to the investigator or sponsor.
• Free of any clinically significant disease (other than the primary hematologic disease) that would interfere with the study evaluations.
• Subjects must be willing to give written informed consent and able to adhere to dosing, study visit schedule, and mandatory procedures.

You may not qualify if:

• Female subjects who are pregnant, intend to become pregnant, or are nursing.
• Excluded prior treatments. Subjects receiving systemic antifungal therapy (oral, intravenous, or inhaled) for the treatment of proven or probable IFI within 30 days of Enrollment (ie, voriconazole, fluconazole \[FLU\], or itraconazole \[ITZ\]).
• Subjects receiving posaconazole for prophylaxis against IFI 10 days prior to enrollment. (Subjects who are receiving either voriconazole or micafungin for prophylaxis against IFI should discontinue those therapies upon enrollment.)
• Subjects with moderate or severe liver dysfunction at Baseline, defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels greater than two times the upper limit of normal (ULN), or a total bilirubin level greater than two times the ULN.
• Subjects who have taken prohibited medications more recently than the indicated washout period prior to Enrollment.
• Subjects who must take prohibited medications during the study.
• Subjects who are in a situation or have any condition that, in the opinion of the investigator, may interfere with optimal participation in the study.
• Subjects who have used any investigational drugs or biologic agents other than their chemotherapy regimens within 30 days of study entry.
• Subjects who are part of the staff personnel directly involved with this study.
• Subjects who are a family member of the investigational study staff.
• Prior enrollment in this study.
• Subjects with a history of hypersensitivity or idiosyncratic reactions to azole agents.
• Subjects with Eastern Cooperative Oncology Group (ECOG) performance status \>2 prior to induction chemotherapy for their underlying disease.
• Subjects with proven or probable invasive or systemic fungal infection at Baseline.
• Subjects with a history of acute lymphoblastic leukemia or chronic myelogenous leukemia without blast crisis.

Sponsors & Collaborators

• Merck Sharp & Dohme LLC: lead

Related Publications (1)

• Cornely OA, Helfgott D, Langston A, Heinz W, Vehreschild JJ, Vehreschild MJ, Krishna G, Ma L, Huyck S, McCarthy MC. Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection. Antimicrob Agents Chemother. 2012 May;56(5):2652-8. doi: 10.1128/AAC.05937-11. Epub 2012 Jan 30.

  PMID: 22290953 RESULT

MeSH Terms

Conditions

Mycoses; Leukemia, Myeloid, Acute; Neutropenia

Interventions

posaconazole

Condition Hierarchy (Ancestors)

Bacterial Infections and Mycoses; Infections; Leukemia, Myeloid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases; Agranulocytosis; Leukopenia; Cytopenia; Leukocyte Disorders

Results Point of Contact

• Title: Senior Vice President, Global Clinical Development
• Organization: Merck Sharp & Dohme Corp.

ClinicalTrialsDisclosure@merck.com

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 27, 2008
• First Posted: May 30, 2008
• Study Start: December 1, 2007
• Primary Completion: April 1, 2009
• Study Completion: April 1, 2009
• Last Updated: April 7, 2017
• Results First Posted: May 14, 2010

Record last verified: 2017-03

Data Sharing

• IPD Sharing: Will share